Cagrilintide is a long-acting synthetic amylin analog studied for its effects on satiety, energy intake, and metabolic regulation. Researchers often pair it with other GLPs receptor agonists, since the two pathways complement one another: GLP-1 analogs primarily support glycemic control and insulin signaling, while Cagrilintide reinforces appetite suppression and slows gastric emptying. This dual-pathway approach makes Cagrilintide an important tool for investigating weight management strategies, metabolic balance, and the interplay between gut–brain signaling systems. Its extended half-life allows researchers to explore prolonged effects, especially when combined with other GLP-1 compounds, offering a more complete model of how multi-hormone therapies might influence appetite regulation and energy balance.
$90.00
Disclaimer: This is a research chemical only. It’s not a medication, and it’s not approved for human or animal use outside of authorized studies
| Molecular Formula | C₁₉₄H₃₁₂N₅₄O₅₉S₂ (for the non-protonated base form) |
| Molecular Weight | Approximately 4,409.01 Da (for the full modified peptide) |
| PubChem CID | 164,618,153 (cagrilintide (acetate) form) Also cross-linked / alternate entries: 167,312,356 in PubChem and other databases. |
| CAS # | 1415456-99-3 |
Cagrilintide is a synthetic, long-acting amylin analog engineered through peptide modification and lipidation to enhance stability, receptor affinity, and systemic half-life. Structurally, it retains the core pharmacophore of endogenous amylin but incorporates amino acid substitutions and a lipid tail, enabling prolonged binding to albumin in circulation. This modification reduces renal clearance and extends its pharmacokinetic profile, permitting sustained exposure in experimental models.
At the receptor level, cagrilintide is a selective agonist of the calcitonin receptor (CTR) and amylin receptor complexes (AMYRs), both of which are implicated in appetite regulation, satiety signaling, and glucose metabolism. By engaging these pathways, it is frequently studied alongside GLP-1 receptor agonists to evaluate combinatorial effects on weight regulation, energy expenditure, and glycemic control.
Preclinical and early clinical investigations highlight its potential to modulate central appetite circuits, delay gastric emptying, and improve cardiometabolic markers in obesity and type 2 diabetes research models. Its extended duration of action—spanning days rather than hours—makes it especially valuable for chronic dosing paradigms in controlled laboratory environments.
Researchers also examine cagrilintide for its role in neuroendocrine signaling, mitochondrial energy regulation, and adiposity reduction. The compound’s structural modifications and pharmacological profile place it within the next generation of metabolic research agents, distinct from classical short-acting amylin analogs.
Reviews
There are no reviews yet.